EUVIMEDEUVIMED entdecken
Crossref

Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting

Xiaoyan Wang, Guodong Liu, Tian Huan, Yuxing Wang, Bo Jiang, Wei Liu, Anran Dai, Xiangzhi Zhang, Feng Yu

Human Cell · 2024

DOI: 10.1007/s13577-024-01088-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Xiaoyan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Proto-Oncogene Proteins c-bcl-2, ErbB Receptors, Apoptosis. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Suqian Sci & Tech Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Engineered T cells expressing chimeric antigen receptors (CARs) have shown remarkable therapeutic effects on haematological malignancies. However, CART cells are less effective on solid tumours mainly due to their weak persistence, which might be caused by activation-induced cell death (AICD). To overcome this limitation, CART cell with the antigen, Epidermal growth factor receptor variant III (EGFRvIII), targeting was modified to carry the anti-apoptotic molecule B cell lymphoma 2 (Bcl-2), and the final construct was named as EGFRvIII·CART-Bcl2 cells. Compared with the EGFRvIII·CART cells, EGFRvIII·CART-Bcl2 cells revealed higher capacities of proliferation, anti-apoptosis and tumour cell killing in vitro. Moreover, EGFRvIII·CART-Bcl2 cells had a longer persistence rate and exerted better anti-tumour effects than EGFRvIII·CART cells in cervical carcinoma xenograft model. Taken together, our findings suggest that incorporating anti-apoptotic molecules into CART cells may enhance its therapeutic effects against solid tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenProto-Oncogene Proteins c-bcl-2ErbB ReceptorsApoptosisHumansAnimalsFemaleCell ProliferationMolecular Targeted TherapyUterine Cervical NeoplasmsImmunotherapy, AdoptiveCell Line, TumorT-LymphocytesDisease Models, AnimalMiceXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AICDBcl-2CARTEGFRvIIISolid tumour

Substanzen

Receptors, Chimeric AntigenProto-Oncogene Proteins c-bcl-2ErbB Receptorsepidermal growth factor receptor VIIIBCL2 protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.
  • Department of General Surgery, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.
  • School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China.
  • School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China. yufeng@ujs.edu.cn.

Förderung

  • Suqian Sci & Tech Program

Zitieren

APA

Wang, X., Liu, G., Huan, T., Wang, Y., Jiang, B., Liu, W., Dai, A., Zhang, X., & Yu, F. (2024). Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting. Human Cell. https://doi.org/10.1007/s13577-024-01088-5

Vancouver

Wang X, Liu G, Huan T, Wang Y, Jiang B, Liu W, et al. Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting. Human Cell. 2024. doi:10.1007/s13577-024-01088-5

BibTeX
@article{Wang2024,
  author = {Wang, Xiaoyan and Liu, Guodong and Huan, Tian and Wang, Yuxing and Jiang, Bo and Liu, Wei and Dai, Anran and Zhang, Xiangzhi and Yu, Feng},
  title = {Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting},
  journal = {Human Cell},
  year = {2024},
  doi = {10.1007/s13577-024-01088-5}
}
Kostenlos starten →